No Data
Aimen vaccine (06660.HK) recommends adopting a share reward plan.
On April 17, Gelonghui announced that Aimee Vaccine (06660.HK) proposed to accelerate the application process for the suggested listing on the A-shares to promote the development of the company's Business. The Board of Directors recommends adopting a stock reward plan for key personnel in core positions of the group. Currently, the total number of company shares involved in all rewards and/or Options granted under the proposed stock reward plan is expected to not exceed 5% of the total issued shares on the day the stock reward plan is adopted. The rewards under the stock reward plan can take the form of shares Options or restricted shares of Listed in Hong Kong and domestic shares. The grant price or exercise price of the rewards or Options granted under the stock reward plan is expected to be based on.
Aimee Vaccine (06660): Changes in the composition of the committees under the Board of Directors.
Aimei Vaccine (06660) announced that Wang Aijun has resigned as a non-executive Director and a member of the compliance and risk control committee; and...
Aimei Vaccine (06660): Jia Shaojun has been appointed as the company's president.
Aimee Vaccine (06660) announced that Mr. Jia Shaojun, the company's Executive Director, Executive President, and Chief Operation Officer, has been appointed...
Express News | AIM Vaccine Co Ltd - Shaojun Jia Appointed as President of AIM Vaccine
AIM Vaccine Co., Ltd. Announces Director Resignations and Committee Reorganization
The serum-free rabies vaccine from Aimee has been accepted for market registration, and institutions predict that there is significant room for the recovery of the Company Valuation.
Hong Kong, April 8, 2025 /PR Newswire/ -- Domestic vaccine leader – Aiwei Vaccine (06660.HK) issued an announcement on April 7 that the registration for the market launch of its serum-free iterative rabies vaccine has received the "Acceptance Notice" from the National Medical Products Administration. In addition, the vaccine has obtained the corresponding product production license. Currently, there is no serum-free rabies vaccine approved for sale in the global market, and this product is expected to become the first to be launched. Aiwei Vaccine is rapidly advancing the launch process of its iterative L products, which justifies the optimistic forecasts of investment Institutions. As noted in the research report published by FOSUN INTL Securities on April 3.
AIM Vaccine Insider Ups Holding By 649% During Year
